Aakash Desai, Assistant Professor at UAB O’Neal Comprehensive Cancer Center, shared an article Antonio Calles and colleagues authored post on X:
“In JTO online, LUPER: lurbinectedin + pembrolizumab in SCLC
• RR: 46.4% (3 CR)
• DOR: 7.8m | PFS: 4.6m | OS: 10.5m
My Takeaway? Limited impact—IO is standard in 1L, and emerging 2L options post-IO show strong efficacy as well.”
Authors: Antonio Calles et al.
